The UK charity for Waldenstrom’s macroglobulinaemia – a rare type of blood cancer
Support Line: 0300 373 8500

Showing only trials that are Wales

Rituximab and Ibrutinib (RI) versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström’s Macroglobulinaemia (RAINBOW)
Is ibrutinib and rituximab a more effective first-line treatment than the current standard first-line treatment for people with WM?
Expected to end: 01/03/2030
Study to Evaluate CCS1477 in Haematological Malignancies
Finding out more about a new type of targeted treatment
Expected to end: 30/06/2025